ReviewOrphanet journal of rare diseases2025
PHACE syndrome: looking backward and forward.
Review in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematic Review and Meta-Analysis of the Efficacy and Safety of Propranolol Versus Other Drugs in the Treatment of Infantile Hemangioma.Journal of cosmetic dermatology · 2026Pooled it
- PHACE syndrome in an infant: the importance of multidisciplinary screening in extensive facial infantile haemangiomas.BMJ case reports · 2026Article
- The Regression Heterogeneity Pattern of Infantile Haemangiomas after Treatment with Propranolol: A Multicentre Retrospective Study.Acta dermato-venereologica · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
PHACE syndrome rarely occurs in patients with infantile hemangioma (IH) but is common in patients with segmental IH involving the head and face. PHACE syndrome involves at least one system abnormality, including arterial abnormalities, structural brain abnormalities, cardiovascular abnormalities, eye abnormalities, and ventral or midline abnormalities. The pathogenesis of PHACE syndrome remains unclear, and it affects various systems in diverse ways. Oral propranolol has good effects on patients with PHACE syndrome. However, there are great challenges in the management of patients with PHACE syndrome in the later stage, including headaches, stroke, neurodevelopment impairment, psychosocial impacts, and poor quality of life. Therefore, this review summarizes the epidemiology, risk factors, pathogenesis, clinical manifestations, diagnosis, treatment, and complications of PHACE syndrome. The latest research on and therapeutic prospects for PHACE syndrome are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.